According to a study done by Kate Rittenhouse-Olson, Ph.D., the monoclonal antibody developed by researchers at the University at Buffalo has been shown to extend// significantly the survival of mice with human breast-cancer tumors.
The study also finds that the antibody inhibits the cancer's spread to the lungs in the animals by more than 50 percent. The results of this study were published in the November 2006 issue of Journal Neoplasia.
The antibody, named JAA-F11, targets a particular disaccharide, an antigen known as TF-Ag, which aids the adhesion and spread of certain cancer cells. While the antibody did not kill the cancer cells, it blocked stages of cancer-cell growth that allow the cells to adhere to organ tissue, the research showed.
Mice with breast-cancer tumors that received the antibody had a median survival time of 72 days, compared to 57 days for the animals that did not receive JAA-F11, the study found. In addition, exposing cultures of tumor cells to the antibody inhibited cell growth by a statistically significant 16 percent.
Kate Rittenhouse-Olson, Ph.D., associate professor of clinical and laboratory sciences in the UB School of Medicine and Biomedical Sciences, is senior author on the study.
"This antibody binds with a carbohydrate on the tumor cell surface that is involved in adhesion of the cell during the metastatic process," said Rittenhouse-Olson. "Not only would drugs attached to the antibody JAA-F11 bind to the tumor cell surface to direct their cytotoxic effect, but the binding of the antibody itself would block the cell from metastasizing."
The antibody was tested using in vitro models of tumor cell growth, in assays to determine its ability to damage or kill cells (cytotoxicity), in various models of cancer metastasis, and, finally, in mice with metastatic breast cancer.
"In addition to providing a survival advantage," said Rittenhouse-Olson, "JAA-F11 immunotheraPage: 1 2 Related medicine news :1
. Long-Term Survival can be Predicted by a Simple Lung Test2
. Hepatitis G May Boost HIV Survival3
. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"4
. Longer Lung Cancer Survival 5
. ICU Survival can be improved by Antibiotic use6
. Vasopressin Found To Boost Survival In Sudden Cardiac arrest7
. Improving Survival Rate Of Lung Cancer Patients8
. Combination Therapy Effective In Improving Lung Cancer Survival9
. Symptoms Found To Be A Good Predictor Of Cancer Survival10
. Survival Of Colon Cancer Patients 11
. Public Defibrillators Found To Improve Survival Rate